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Abortion, resulting from infections by the parasite Neospora caninum, is a major cause of economic loss to 
both the dairy and beef industries of cattle-producing countries of the world. Vaccination as a means of 
preventing abortion and/or infection represents a viable control strategy; indeed a commercial vaccine is 
available in some countries, albeit of unknown efﬁcacy. The  commercial vaccine is based on inactivated 
tachyzoites of N. caninum but other approaches based on lysates and recombinant antigens of N. caninum 
may also be feasible. In  this study we have used an immunisation/challenge model of  transplacental 
transmission, based on the Qs mouse with an Nc-Liverpool challenge, to investigate the vaccine potential 
of a number of formulations based on four recombinant proteins of N. caninum (GRA1, GRA2, MIC10, and 
p24B). All formulations studied were immunogenic in the mouse when assessed by ELISA using sonicated 
tachyzoite antigen as  the target antigen. In  one experiment, a  mixture of  MIC10 and p24B produced 
partial protection against transplacental transmission of  N. caninum in  this mouse model; in  contrast 
a live infection of tachyzoites of NC-Nowra given before pregnancy always induces very high levels of 
protective immunity. The ﬁeld of vaccines against Neospora-associated abortion in cattle is discussed. 
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1.  Introduction 
 
Abortion, resulting from infections by the parasite Neospora can- 
inum, is  a  major cause of  economic loss  to both the dairy and 
beef industries in  Australia  and other cattle producing countries 
of the world. Annual losses in calf and milk production were esti- 
mated to be $21 million in Australia alone [1]. Infections in dogs (if 
caught early enough) may be treated with drugs however treatment 
options in food-producing animals are  limited. Hence, efﬁcacious 
vaccines for  the control of  neosporosis are  urgently needed, as 
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infections are  now recognised as  exceedingly common in  cattle 
[2]. 
Vaccines based on live parasites are available for a range of other 
diseases and used successfully and extensively around the world. 
For example, live vaccines are available for besnoitiosis in cattle [3], 
Toxoplasma-induced abortion in sheep [4] and coccidiosis in poultry 
[5].  It is signiﬁcant that all  these successful vaccines are  against 
coccidia that are  closely related to N. caninum. The  success of the 
live  vaccine against Toxoplasma gondii-induced abortion in  sheep 
demonstrates that foetal loss  is preventable, raising the prospect 
that a vaccine to prevent Neospora-associated abortion should be 
feasible. Transmission of the parasite from dam to offspring is the 
major route of infection for N. caninum, and controlling that route of 
the life cycle  of the parasite is potentially needed as a prerequisite 
for a vaccine that prevents abortions. 
A vaccine for  the prevention of  neosporosis in  cattle should, 
at a minimum, prevent abortion in  cattle. A commercial vaccine 
against bovine neosporosis based on  an  inactivated N. caninum 
tachyzoite preparation [Bovilis®  Neoguard, Intervet] is  available 
in  some countries of the world. An evaluation of this vaccine in 
ﬁeld studies [6–9] showed that vaccination with Bovilis®  Neo- 
guard  did   reduce the  incidence of  abortion. Heuer et  al.  [8] 
reported a 24.6% reduction in abortion when compared to controls 
for   Bovilis®   Neoguard. Barajas-Rojas et  al.  [6]   describe  abor- 
 
. 
  
 
 
 
tion rates of 12% and 29% in  vaccinated and placebo groups, 
respectively. 
Recombinant vaccines preventing neosporosis in cattle will have 
the advantage of  being cheaper to manufacture, and a  focussed 
selection of the relevant antigens involved might also  be  able to 
selectively target immune responses that are  important in the pre- 
vention of abortion as  opposed to preventing infection. In recent 
years, studies on the molecular characterisation of N. caninum have 
resulted in the molecular cloning of a variety of genes coding for 
antigens [10,11]. Many of these antigens represent potential new 
vaccine candidates. The approaches used for gene discovery to date 
have focussed on immunoscreening cDNA expression libraries [12] 
or the generation of expressed sequence tags (ESTs [13]). Such stud- 
ies have resulted in the isolation of homologues of genes previously 
described in T. gondii,  such as the SAG, GRA and MIC genes, all of 
which are intimately involved in the invasion process of the host 
cell  and therefore important in  determining the outcome of  the 
parasite/host relationship. 
Animal models, both mouse and cattle, exist to evaluate many of 
these candidates for their potential as vaccines against neosporo- 
sis [14,15]. In this study we  have used an  immunisation/challenge 
mouse model of  transplacental transmission to investigate the 
vaccine potential of a number of formulations based on  four 
recombinant proteins of  N.  caninum (GRA1,  GRA2,  MIC10,  and 
p24B).  The ﬁrst three of these proteins were chosen since they are 
excreted/secreted by N. caninum during the active invasion process 
of a host cell, and thus thought to represent key molecules involved 
in the initiation of infection. The protein p24B was included because 
no  knowledge was available about this molecule from the litera- 
ture on cyst-forming coccidia, and database searches implied it was 
potentially a novel protein. 
 
2.  Materials and  methods 
 
2.1.  Parasites 
 
N. caninum tachyzoites of  NC-Nowra and  NC-Liverpool were 
maintained by  continuous cell  passage in  Vero  cells  (using  RPMI 
and heat inactivated horse serum) at 37 ◦C in an  atmosphere con- 
taining 5% CO2 . Parasites were harvested from culture and then 
passed through a  26G  needle to lyse  any  remaining intact Vero 
cells.  Tachyzoites were centrifuged at 500 g for 10 min and the pel- 
let resuspended in sterile 0.9% saline. Parasites were counted using 
a Neubauer haemocytometer and diluted in  sterile 0.9% saline to 
achieve the required dose for injection [14]. 
A lysate from NC-Nowra tachyzoites was prepared  as  follows. 
Pellets were resuspended in  lysis  buffer (20 mM  Tris–Cl  pH  7.5, 
0.15 M  NaCl,  1% Triton  X-100, 1 mM  Ethylenediaminetetraacetic 
acid,   1 mM   Benzamidine, 1 mM   Phenymethylsulphonyl ﬂuoride 
and 2 mM Dithiothreitol) and incubated on ice for 1 h. The suspen- 
sion was then sonicated three times at 50 W/20 KHz for  15 s and 
spun at 3000 g for 10 min to remove insoluble debris. The lysate was 
dialysed overnight at 4 ◦C against PBS and the protein concentration 
was determined using a Lowry protein assay. 
 
2.2.  24B Characterisation 
 
2.2.1.   Identiﬁcation and  characterisation of 24B cDNA 
A cDNA  library from Nc-Liverpool was used in  these studies 
[12].  A recombinant phage plaque from this library (called 24B), 
chosen randomly from the library,  was picked into double dis- 
tilled water and subject to PCR ampliﬁcation  using primers  FpB 
(5tGTAAAACGACGGCCAGT3t)  and RpB2  (5tGCCGCTCTAGAACTA3t) 
whose priming sites ﬂank the cloning site.  A 50 �l PCR reaction 
was used with 2.5 mM  MgCl2 , 200 �M dNTP, 25 pmol primer with 
cycling conditions, 1 cycle, 95◦C, 3 min; 25 cycles, 95◦C, 1 min, 52◦C, 
1 min, 72◦C, 2.5 min and 1 cycle,  72◦C, 5 min. The PCR product was 
run on  a 1%  agarose gel  to estimate size  and amount of product 
obtained. The  PCR product was then puriﬁed using a Qiagen col- 
umn and sequenced completely by cycle  sequencing and the aid of 
an ABI automated sequencer. A variety of primers, generating over- 
lapping PCR products, were designed to complete the sequence of 
the EST by PCR and sequencing (not shown). 
Analyses of the 24B sequences were performed in various ways. 
The  non-redundant nucleotide sequence database maintained by 
the National Center for Bioinformatics (NCBI) and the Apicomplexa 
nucleotide sequence database at the Parasite Genome Blast Server 
(PGBS;   http://www.ebi.ac.uk/parasite/parasite blast server.html) 
were  searched  with  the  sequences  obtained  using  the  pro- 
grams BlastN   and TBlastX  in  order to detect homologies with 
nucleotide sequences currently in  the nucleotide sequence 
databases.  Further  searches were  also   made  of  speciﬁc  para- 
site databases of ESTs and genomic sequences (e.g.  ToxoDB; 
http://www.toxodb.org/toxo/home.jsp). ESTs of N. caninum, homol- 
ogous to 24B, were identiﬁed by BLAST searching of an EST database 
(http://compbio.dfci.harvard.edu/tgi/protist.html). 
 
 
2.2.2.   Cloning of 24B into  pET25b 
PCR  was  carried   out  with   primers   pET25-24BORF2F (5t   - 
ACGCATGAATTCTATGGATCCTAAAGTGGAGAGT   -  3t)   and  pET25- 
24BORF2R2   (5t  - CATGACCTCGAGGACGCGCGGAACACCGTA  - 3t) 
using PCR  cycling conditions  as   follows  94◦C × 2 min 1  cycle; 
94◦C × 45 s,  50◦C × 45 s,  72◦C × 1.5 min 28   cycles  72◦C × 5 min  1 
cycle.  The  PCR product was puriﬁed using a Qiagen PCR puriﬁca- 
tion kit and then digested at 37◦C for 3 h with EcoRI and XhoI. The 
restriction digest was then puriﬁed with a Qiagen kit  before lig- 
ation. Ligation was performed overnight at 4◦C  with  EcoRI/XhoI 
cut  pET25b vector. The ligation was transformed into Top10 com- 
petent cells  and recombinants selected on  agar plates containing 
ampicillin. Recombinant colonies were screened using vector based 
primers (T7 promoter 5tTTAATACGACTCACTATAGGG3t and T7 ter- 
minator 5t  GCTAGTTATTGCTCAGCG3t)  to assess the size   of  the 
insert. A selection of colonies that appeared to have the correct 
insert size  was then sequenced to check the integrity of the con- 
struct. 
 
 
2.2.3.   Puriﬁcation of His-tagged 24B from E. coli 
Escherichia coli  (containing recombinant  pET25b) from 50 ml 
L-broth cultures were pelleted and resuspended in  4 ml  of  lysis 
buffer (50 mM  NaH2 PO4 , pH 8.0, 300 mm NaCl, 10 mm imidazole) 
containing lysozyme. After lysis  by sonication the cell  debris was 
removed by centrifugation and recombinant protein was bound to 
a Ni-NTA resin by mixing for 1 h at 4◦C after which the slurry was 
transferred to a 5 ml  disposable column (Qiagen). Contaminating 
proteins were removed by  washing the  column with  8 × 5 ml 
washes  with  50 mM   NaH2 PO4 ,  pH   8.0,   300 mm  NaCl,  20 mM 
imidazole, 2 × 5 ml washes with 50 mM  NaH2 PO4 , pH 8.0, 300 mM 
NaCl, 50 mM  imidazole and 2 × 2.5 ml washes of 50 mM  NaH2 PO4 , 
pH  8.0,  300 mM  NaCl,  70 mM  imidazole. Protein was eluted off 
in  2 × 2.5 ml  elutions of 50 mM  NaH2 PO4 , pH  8.0,  300 mm NaCl, 
100 mM  imidazole and 1 × 2.5 ml  elutions of 50 mM  NaH2 PO4 , pH 
8.0,  300 mM  NaCl, 250 mM  imidazole. Elutions were checked for 
the presence of protein by SDS-PAGE and then dialysed against 0.9% 
saline. The amount and purity of protein recovered was estimated 
by assaying with Bradford reagent (Biorad) and SDS-PAGE respec- 
tively and then the protein was lyophilised and stored at −20◦C. A 
sample of the protein was analysed by Western blotting using an 
antibody raised against the His-tag (Qiagen) to verify the presence 
of the fusion protein. 
  
 
 
Table 1 
Assessment of vaccine potential—Experiment 1 
 
Group Treatment Total number of dams/average 
litter size (±S.E.) 
Number of live/dead 
pups/total 
Number of pups/number 
positive for  N. caninum 
% Positive pups 
1 Challenge only 8/13.9 ± 1.4 104/7/111 100/76 76b 
2 VSA-3 control 8/14.5 ± 2.2 112/4/116 104/77 74b 
3 NC-Nowra infection 10/14.1 ± 1.7 127/14/141 123/10 8a , b 
4 NC-Nowra lysate 9/13 ± 2.1 113/4/117 104/65 63a , b 
5 MIC10 6/14.5 ± 1.9 82/5/87 79/52 66 
6 p24B 9/16.1 ± 1.6 122/7/129 105/74 70 
7 MIC10 + 24B 6/16.3 ± 0.8 91/7/98 69/35 51a 
a   Signiﬁcantly different to the control groups. 
b   From Miller et al. [14], Table 2, Experiment 3. These experiments were conducted at the same time as those shown in this table and so the data is directly comparable. 
 
2.3.  Cloning and  expression of GRA1, GRA2 and  MIC10 
 
Similar procedures as described above were used for the expres- 
sion and analysis of these molecules. 
 
2.3.1.   Expression of NC-GRA1 in E. coli 
DNA from an  EST previously identiﬁed bearing sequence 
homology to GRA1 was used as  a template. PCR was performed 
with  primers  pTrcHisp24-F (5t   ACGGATGGATCCTATGCTAGGTG- 
GCGGGCG3) and primer FpB to generate a PCR product from this EST 
that was digested to completion with BamH1 and Kpn1. The product 
was ligated into doubly digested (BamH1 and Kpn1) pTrcHis vector 
and transformed into E. coli strain TOP10 and recombinants identi- 
ﬁed by section on LB plates containing ampicillin (LBamp). Colonies 
were screened by PCR using primers pTrcHisp24-F and pTrcHisP24- 
R (5tTACCGAGAATTCCGCTAACCCATGCCGTCG3t) and sequencing to 
check for the presence of inserts that were correctly in frame. 
For protein puriﬁcation cultured bacteria were resuspended in 
10 ml  of lysis  buffer (20 mM  sodium phosphate, 500 mM  NaCl pH 
7.8)  containing 0.1 ml  protease inhibitors (Sigma Cat. No. P-8849). 
Cells  were lysed by  freeze/thawing three times in  liquid nitro- 
gen/37 ◦C water bath and sonicated for 2 × 30 s at 50 W/20 kHz. Cell 
debris was removed by  centrifugation at 10,000 g and the super- 
natant (corresponding to the soluble fraction) retained. 
Recombinant protein was puriﬁed from the supernatant by Ni- 
NTA agarose afﬁnity chromatography. Contaminating proteins were 
eliminated by  washing the resin with 20 mM  sodium phosphate, 
500 mM  NaCl pH 6 followed by washes with 20 mM  sodium phos- 
phate, 500 mM  NaCl pH 5.5.  Fusion protein was then eluted from 
the resin using 20 mM sodium phosphate, 500 mM NaCl pH 4. Yield 
per 50 ml aliquot from a large culture was estimated at 250 �g. 
 
2.3.2.   Expression of NC-GRA2 in E. coli 
The  cloning of  the GRA2  ORF  into  the  pTrcHis vector was 
previously described [12].   Large-scale growth  and induction  of 
expression was done as described above for  GRA1. Small-scale 
expression experiments demonstrated that most of the GRA2 was 
primarily present in  the insoluble subcellular fraction so  it  was 
puriﬁed under denaturing conditions as  follows. Bacteria were 
resuspended in  4 ml  of  lysis  buffer (6 M  Guanidiniun HCl, 0.1 M 
NaH2 PO4 , 0.01 M Tris–Cl, pH 8.0 or 8 M urea, 0.1 M NaH2 PO4 , 0.01 M 
Tris–Cl, pH 8.0) plus protease inhibitors and lysoszyme. They  were 
incubated on  ice  for  30 min and then sonicated for  2 × 10 s  at 
50 W/40 kHz. Cell debris was removed by centrifugation at 10,000 g. 
Recombinant protein was puriﬁed from the supernatant by Ni-NTA 
agarose afﬁnity chromatography. Resin  was washed with 8 M urea, 
0.1 M NaH2 PO4 , 0.01 M Tris–Cl  pH 6.3 and protein was then eluted 
using four  column volumes of  8 M  urea, 0.1 M  NaH2 PO4 , 0.01 M 
Tris–Cl pH5.9 and four  volumes of 8 M urea, 0.1 M NaH2 PO4 , 0.01 M 
Tris–Cl pH 4.5. 
 
2.3.3.   Expression of NC-MIC10 in E. coli 
The  cloning of  MIC10  was previously described by  us  (pre- 
viously known  as   P20)   [16].   RACE Ready  cDNA  was  used  as 
a   template  for   PCR  using  gene  speciﬁc  primers  p30-ATG2F 
(5tACGTATGGATCCGGCTTTGTCTACGATGAAC3t)  and pET25-p20R4 
(5tACGTATAAGCTTTGCCTTCTTGCGGGCCGCGA3t). The PCR product 
was puriﬁed and doubly digested with the enzymes BamH1 and 
Hind111, after which the product was further puriﬁed and ligated 
into BamH1 and Hind111 digested pET25b vector.  Recombinants 
were selected by transformation into E. coli as described for 24B and 
clones for expression studies were screened by PCR and sequencing 
as described above. 
 
2.4.  Assessment of Vaccine Potential 
 
Two independent experiments were conducted (Tables 1 and 2) 
using the immunization strategy and mouse model described in 
detail elsewhere  [14,17]. Brieﬂy female Qs mice at 4–5  weeks of 
age  were divided into groups that were injected subcutaneously 
 
Table 2 
Assessment of vaccine potential—Experiment 2 
 
Group Treatment Total number of dams/average 
litter size (±S.E.)a 
Number of live/dead 
pups/total 
Number of pups/number 
positive for  N. caninum 
% Positive pups 
1 Uninfected mice 11/12.1 ± 2.2 97/25/122 95/0 0b 
2 Challenge only 13/13.1 ± 2.7 118/24/142 93/62 74b 
3 VSA-3 control 14/12.8 ± 1.9 151/49/200 124/79 64b 
4 NC-Nowra lysate 12/14.6 ± 1.5 131/1/132 114/60 53b 
5 GRA-1 12/15.0 ± 1.2 150/3/153 141/87 63 
6 GRA-2 12/8.1 ± 2.7 65/46/111 55/37 70 
7 MIC10 11/11.4 ± 2.2 80/36/116 70/47 64 
8 p24B 10/14.5 ± 1.9 87/0/87 83/50 60 
9 All 4 antigens 9/8.6 ± 2.4 43/4/47 42/26 60 
10 MIC10 + p24B 12/15.0 ± 2.5 120/12/132 95/72 76 
a   Average litter size includes the live pups only, dams with no live pups are included in the calculation as a 0. 
b   From Miller et al. [14], Table 2, Experiment 2. These experiments were conducted at the same time as those shown in this table and so the data is directly comparable. 
  
 
 
(s.c.)  as  detailed in  Tables  1 and 2. VSA-3  was used an  adjuvant 
(comprising 1/3 v/v  of the immunogen) and 10 �g of each recom- 
binant protein or lysate was injected per mouse. Four  weeks later 
the same mice were given a booster s.c. injection of the same for- 
mulation received earlier. 8–11 days later ovulation of the female 
mice was synchronised using pregnant mare serum gonadotrophin 
and human chorionic gonadotrophin, after which the females were 
housed overnight with stud males. Females  were inspected for 
the presence of vaginal plugs and only the plugged females were 
kept for  inclusion in  the experiment (becoming the treatment 
groups). Unplugged mice were kept until challenge of the treat- 
ment groups, at which time they were euthanized to provide blood 
for immunoassay. 
On day  5 of gestation, pregnant mice in  the treatment groups 
were injected s.c with 106 tachyzoites of NC-Liverpool recovered 
from in vitro culture as described above. A control group (pregnant 
uninfected mice) were injected s.c.  with 0.9% saline. On  approx. 
day  14 of gestation pregnant dams were placed in individual boxes 
and allowed to carry their pregnancy to term. Mice  were checked 
daily until all  that were obviously pregnant had given birth and 
the date of birth and number of pups (live  and dead) noted. Dif- 
ferences in  average litter sizes and the number of live  and dead 
pups per group were analysed by Chi-square using the Instat pro- 
gram. Seven days after giving birth dams and surviving pups were 
euthanased, pup brains were removed and snap-frozen in  liquid 
nitrogen before being transferred to −20 ◦C for short-term storage. 
Dams were euthanased and blood collected by cardiac puncture for 
analysis of antibody levels. 
All animal experiments were conducted with the approval of the 
UTS Animal Care and Ethics Committee. 
 
2.4.1.   Immunogenicity of the recombinant proteins in mice 
Blood  was collected from unplugged female mice via  cardiac 
puncture and the serum obtained used to demonstrate IgG in the 
mice (by  ELISA) to the recombinant proteins. NC-Nowra (or  NC- 
Liverpool)  tachyzoites were recovered from in  vitro  culture and 
reduced to protein extracts by re-suspension in PBS and disruption 
by  sonication at 50 W/20 KHz for  10–20 s. Protein concentration 
was determined  using the Bradford dye-binding assay (Biorad). 
Costar 96 well plates were coated with antigen diluted to 1 �g/well 
in carbonate buffer (70 mM NaHCO3 , 29 mM Na2 CO3 , 3.1 mM NaN3 , 
pH 9.6)  at 4 ◦C overnight. Extra plates were coated with 1 �g/well 
of the recombinant protein applicable to the group of mice being 
assayed. Plates were washed three times with PBS/0.03%  Tween 
(PBST) and serum diluted 1:100 in  blocking buffer (0.3% Tween, 
0.05% bovine haemoglobin) was added to each well. Each  sample 
was done in  duplicate. Plates were incubated for  90 min at 37 ◦C 
and then washed three times with PBST. Anti-mouse IgG-alkaline 
phosphatase conjugate was diluted 1:6000 in blocking buffer and 
added to wells and plates were incubated at 37 ◦C for  1 h. Plates 
were washed with PBST and 1 mg/ml of p-nitrophenylphosphate 
in carbonate buffer was added. Plates were incubated at 25 ◦C for 
30 min and absorbance at 405 nm read in  a  Biorad ELISA plate 
reader. Statistical analysis was performed using ANOVA and a 
Tukey–Kramer Multiple Comparison test. A P < 0.05 was considered 
signiﬁcant. 
The level of IgG1 and IgG2a antibodies speciﬁc to N. caninum in 
the serum from mice was also  measured by ELISA with the follow- 
ing modiﬁcation. Instead of anti-mouse IgG-Alkaline Phosphatase, 
anti-mouse  IgG1-Biotin and anti-mouse  IgG2a-Biotin antibodies 
were diluted 1:6000 in blocking buffer, added to wells and plates 
were incubated overnight at 4 ◦C.  They  were then washed three 
times with PBST, and Extravidin-Alkaline Phosphatase at a  dilu- 
tion of 1:5000 in  blocking buffer was added to the wells. These 
plates were incubated at 37 ◦C for 1 h after which they were washed 
three times with PBST. p-Nitrophenylphosphate at a concentration 
of 1 mg/ml in developing buffer (58 mM  NaHCO3 , 42 mM  Na2 CO3 , 
2 mM MgCl2 .6H2 O, pH  9.8)  was added to the wells. Plates were 
incubated at 37 ◦C for 15 min and read at an absorbance of 405 nm. 
 
 
2.4.2.   Detection of N. caninum by PCR 
Individual pup brains were homogenised in 4 ml of DNAzol [14]. 
Proteinase K was added to a ﬁnal concentration of 400 �g/ml  and 
tubes were left at room temperature overnight or  until lysis  was 
complete (i.e.  no  undigested tissue visible). 2 ml  of 100% ethanol 
was added and the tube inverted until DNA precipitation was com- 
plete.  The  DNA precipitate was transferred to a  sterile tube and 
washed twice with 70% DNAzol,  30% ethanol and then once with 
75% ethanol. All liquid was removed and the DNA pellet was resus- 
pended in 750 �l sterile water. 2.5 �l of this DNA was used in each 
PCR reaction. PCR was carried out using primers (targeting the 
ribosomal DNA of N. caninum) CR3 (5t-ATATACTACTCCCTGTGAGTT- 
3t)  and CR4  (5t-GTAATCTGAAAGCGAATAGAG)  or   primers  Tim3 
(5t-CCGCTGCAGAGGTGAACCTGCGGAAGGATC-3t)  and Tim  11  (5t- 
CACTGAAACAGACGTACC-3t). Each PCR reaction consisted of 6.7 mM 
Tris–HCl, 1.66 mM (NH4 )2 SO4 , 0.45% Triton X-100, 2 mg/ml gelatin, 
2.5 mM MgCl2,  0.2 mM  dNTPs, 0.25 �M of each primer, and 1.1U of 
Taq polymerase (Biotech). Ampliﬁcations were performed on an MJ 
Research PTC-100. Thermocycling conditions consisted of 1 cycle of 
95 ◦C for 2 min followed by 35 cycles of 95 ◦C for 45 s, 50 ◦C for 45 s, 
72 ◦C for  1 min 30 s. Final  cycle  was 72 ◦C for  5 min. After ampliﬁ- 
cation, 4 �l from each reaction was loaded onto a 1% agarose gel 
and electrophoresed. Gels  were stained with ethidium bromide 
and viewed on a transilluminator and photographed. The presence 
of N. caninum DNA was determined by  the presence of a band of 
appropriate size  in the PCR reaction. The numbers of positive and 
negative pups were tallied for each litter and each group and a per- 
centage of transmission calculated. Percent transmission in groups 
was compared using a Chi-square test. A P < 0.05  was considered 
signiﬁcant. 
 
 
3.  Results 
 
3.1.  Characterisation and  expression of 24B 
 
The sequence compiled for the 24B cDNA was 1744 bp long (56% 
GC; with a poly  A tail  of 47  residues) and it contained a number 
of potential open reading frames (ORFs). A BlastN  search of the NR 
Nucleic Acid database with the 5t untranslated region from the 24B 
cDNA sequence revealed sequence similarities (67% over 50 bases) 
to those found in the 3t untranslated regions of cytokine-like genes 
of mammals such as  MIP-1  (HSMIP1A  [18]) and LD78 (HSLD78A 
[19]). 
Sequence homologies detected to T. gondii  and Eimeria tenella 
sequences by  database searching of parasite sequence databases 
pointed to the ORF being located between positions 628  and 1420. 
This ORF was 729 bp long encoding a 27 kDa polypeptide containing 
243  amino acids. The ﬁrst ATG codon in the 24B gene is located at 
628 bp and is believed to be the start codon of this gene, as it is in a 
favourable context for initiating translation and there are no other 
ATG codons upstream [20]. 
A    BlastN     search   of    the   TIGR    N.    caninum   database 
(http://compbio.dfci.harvard.edu/tgi/cgi-bin/tgi/Blast/index.cgi) 
with the genomic sequence of 24B revealed matches to a cluster 
of  22  ESTs comprising contig TC3100.  All the ESTs were derived 
from tachyzoite cDNAs  conﬁrming the gene is  expressed in  the 
tachyzoite stage. PCR with 24B-speciﬁc primers demonstratrated 
the sequence was derived from the N. caninum genome and not 
Vero, thereby conﬁrming the parasite origin of the sequence. 
  
 
 
Initial attempts to express 24B in the plasmid vector pTrcHisB 
gave a poor yield of protein from standard broth cultures. In addi- 
tion, the protein failed to bind very tightly to the Ni-NTA resin and 
much was lost from the resin during the washing stages. Conse- 
quently cloning of the sequence into pET25b was performed. This 
resulted in much higher levels of p24B  protein expression, which 
could be puriﬁed by Ni-NTA chromatography. The yield of recom- 
binant p24B  per 50 ml culture was estimated at 80 �g. 
 
3.2.  Immunogenicity of recombinant proteins 
 
ELISA was used to conﬁrm the presence of antibodies to N. can- 
inum proteins in sera collected from mice injected with the various 
formulations described in Tables 1 and 2. Examples of the results 
are  shown in Fig. 1, which are derived from Experiment 1. All mice 
injected with lysate or tachyzoites produced high levels of IgG anti- 
body that were detectable by  ELISA using a  lysate of  NC-Nowra 
as  the target antigen (Fig. 1, panels A and B). Mice  injected with 
MIC10 and/or p24B produced responses that were barely detectable 
in this ELISA. However when recombinant protein was used as the 
target antigen in ELISA, antibody to them was detected. 
For example,  a  signiﬁcant amount  of  antibody (P < 0.05)  is 
detectable in  Groups 4 (Nowra lysate), 5 (GRA-1),  6 (GRA-2)  and 
9 (GRA-1/GRA-2/p20/p24B) of Fig. 1 compared with Group 1 (con- 
trol mice) showing an antibody response to the injections of lysate 
or recombinant antigen in these groups. No signiﬁcant difference 
is  seen between Group 1  and Groups 7  (MIC10),  8  (p24B) or  10 
(MIC10 + p24B).  However, when ELISAs were performed using the 
recombinant antigen injected as target antigen, signiﬁcantly higher 
absorbances (P < 0.05) were seen in all the treatment groups com- 
pared with sera from the control mice (Fig. 1; Panel C). 
IgG1 and IgG2a  ELISA’s were also  performed to determine the 
isotype of N. caninum speciﬁc IgG that was produced in  mice as 
a result of injection of the formulations (Fig. 1B). Both the groups 
injected with NC-Nowra lysate and live  NC-Nowra had signiﬁcant 
IgG1 and IgG2a  antibody responses (P < 0.05). The dominant anti- 
body isotype produced in mice injected with NC-Nowra lysate was 
IgG1, compared with a dominant IgG2a antibody response in mice 
vaccinated with live NC-Nowra parasites. 
These results therefore conﬁrmed that at the time of  chal- 
lenge, the injected mice had seroconverted to the antigen injected, 
thereby conﬁrming that all 4 proteins are  immunogens in mice. 
 
3.3.  Assessment of vaccine potential 
 
3.3.1.   Experiment 1 
The results are summarized in Table  1 and transmission of the 
challenge strain was assessed by  PCR of DNA extracted from the 
brains of 684  pups. Some of the data in  Table  1 is from Miller et 
al. [14]  and is reproduced here in order to allow complete repre- 
sentation of these studies. Average litter sizes ranged from 13 ± 2.1 
in  the NC-Nowra lysate group to 16.3 ± 0.8  in  the MIC10 + p24B 
group. There was no signiﬁcant difference in the average litter size 
between any  of the groups. 
The rate of transmission in mice that received only the challenge 
infection (the positive control) was 76%. Signiﬁcant reductions in 
parasite transmission were observed in  some treatment groups. 
Those injected  with  NC-Nowra lysate  showed  transmission  to 
63% of  the pups, a  reduction compared to the controls of  17.8% 
(P = 0.0485). Those injected with live  NC-Nowra only transmitted 
the infection to 8% of  pups; a  reduction in  transmission rate of 
90% (P < 0.0001). Both groups individually injected with recom- 
binant antigens transmitted the challenge to 66%  (MIC10) and 
70% (p24B) of offspring, a reduction of 13.2  and 7.8% respectively. 
However, in the combined recombinant group (MIC10 + 24B)  only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  1. ELISA results for N. caninum speciﬁc IgG antibodies using serum from blood 
taken prior to challenge by NC-Liverpool. Blood was collected from unplugged mice 
on the day plugged mice received a challenge dose of  106  NC-Liverpool. Columns 
represent the mean absorbance for  each group and error bars are S.E. P20 is MIC10. 
(Panel A) The target antigen is lysate from NC-Nowra. Signiﬁcant antibody responses 
were observed in mice injected with NC-Nowra lysate and live NC-Nowra para- 
sites, compared to mice injected with saline (P < 0.05). Assay is for IgG.  (Panel  B) 
The target antigen is  lysate from NC-Nowra. ELISA proﬁles shown are for IgG1   
and IgG2a • . Signiﬁcant IgG1  antibody responses were observed in mice injected 
with NC-Nowra lysate and live NC-Nowra tachzyoites, compared with mice injected 
with saline (P < 0.05). Signiﬁcant IgG2a antibody responses were also observed in 
these mice, compared with mice given saline (P < 0.05). The dominant antibody iso- 
type produced in mice injected with NC-Nowra lysate was IgG1,  in contrast mice 
injected with live NC-Nowra tachzyoites produced IgG2a as the dominant antibody 
isotype. (Panel C) The target antigen is either recombinant MIC10  or p24B protein 
• . Mice injected with MIC10 + p24B had a signiﬁcantly greater MIC10 speciﬁc anti- 
body response than mice vaccinated with MIC10 alone or saline (P < 0.05). Both mice 
injected with p24B alone and MIC10 + p24B had a signiﬁcant p24B speciﬁc antibody 
response, compared with mice given saline (P < 0.05). 
 
 
 
51%  of  offspring were  positive,  a  reduction of  transmission  of 
32.9% (P = 0.0009). The best performing “vaccine” was therefore live 
NC-Nowra. Within most groups once again, individual litter trans- 
mission  rates  were  variable. For example  in the NC-Nowra lysate 
group, rates varied from 13% to 100% transmission and in the p24B 
group rates varied from 0% to 100% transmission. 
  
 
  
 
 
 
Fig. 2.  Neospora caninum speciﬁc antibodies were detected by ELISA in serum from 
dams that had produced pups. (A) IgG and (B) IgG1   and IgG2a • . Columns rep- 
resent the mean absorbance for  each group and error bars are S.E. P20 is  MIC10. 
All  groups of  mice had an IgG  antibody response after challenge (A).  All  groups 
produced similar levels of  IgG2a antibodies and this was the dominant antibody 
isotype produced by all groups, except those mice that had previously been injected 
with NC-Nowra lysate. The level of IgG1  antibodies produced was variable among 
the mice groups, with the highest levels produced in the NC-Nowra lysate injected 
group (B). 
 
 
All groups of mice after birth of their pups demonstrated an N. 
caninum speciﬁc IgG antibody response (Fig. 2A) that was enhanced 
by  the challenge  given during  pregnancy  with NC-Liverpool. The 
level of antibody produced in  groups injected with recombinant 
proteins appeared lower than the level produced in the other four 
groups. IgG1 and IgG2a ELISA’s were also performed on these serum 
samples, to see  whether immunisation altered the type of IgG iso- 
type produced after a parasite challenge. The  dominant antibody 
isotype in all groups was IgG2a,  except the group vaccinated with 
NC-Nowra lysate, where  IgG1  remained the dominant antibody 
isotype (Fig. 2B). 
 
3.3.2.   Experiment 2 
Table  2 shows the results of our  second experiment to deter- 
mine the ability of a range of formulations to prevent transplacental 
transmission of an  N. caninum challenge during pregnancy. Some 
of this data is from Miller et al. [14] and is reproduced here in order 
to allow complete representation of these studies. The percentage 
of dams who did  not give  birth or who only had dead pups varied 
considerably, however, a Chi-square analysis showed no signiﬁcant 
difference between the groups. There was also  no  signiﬁcant dif- 
ference in  the average litter size  for  each group compared with 
the uninfected and the infected control. However, the numbers of 
live  pups in the treatment groups do  differ signiﬁcantly (P < 0.05) 
from each other. Group 9 (GRA-1/GRA-2/MIC10/p24B) has  a signif- 
icantly lower number of live pups compared with Group 4 (Nowra 
lysate; P = 0.019) and Group 5 (GRA-1;  P = 0.08). Group 6 (GRA-2) 
is  also  signiﬁcantly lower than Group 5  (GRA-1;  P = 0.0266) and 
Group 10  (MIC10 + p24B; P = 0.038). There was no  signiﬁcant dif- 
ference in the number of stillborn pups per group seen in Groups 
1, 2, 3  or 9, however,  the number of  stillbirths was signiﬁcantly 
lower compared with the uninfected control in Groups 4 (Nowra 
lysate; P < 0.001), 5 (GRA-1;  P < 0.001), 8 (p24B; P < 0.001) and 10 
(MIC10 + p24B; P = 0.0124) and signiﬁcantly higher (P = 0.0006) in 
Group 6 (GRA-2).  Groups 4 (P < 0.001), 5 (P < 0.001), 7(P = 0.0114) 
and 8 (P < 0.001) had a signiﬁcantly lower number of stillbirths and 
Group 6 (P < 0.001) a signiﬁcantly higher number of stillbirths than 
the infected control (Group 2). 
DNA was extracted from 927 of the 931 pups collected. The DNA 
from 4 of the samples was lost during the extraction process. PCR 
was done at least once on all remaining samples. All samples which 
gave a faint positive result were repeated and around 100  samples 
were randomly repeated to verify the results. Any unclear results 
obtained in the PCR using the CR3/CR4 primers were repeated with 
the Tim3/Tim11 primers for  veriﬁcation. The  results obtained are 
summarized in  Table  2. An overall transmission of 74 ± 6.6% was 
found in  the challenge-only control group (Group 2)  with trans- 
mission rates varying from 48%  to 100%  amongst the litters. No 
evidence of  transmission was found in  the saline control group 
(which was not infected). 
None of the treatment groups had a signiﬁcantly reduced rate 
of fetal infection compared with the positive control group (Group 
2). Transmission rates of N. caninum did  vary however extensively 
among the various treatment groups. For example, transmission in 
the group injected with NC-Nowra lysate was 50.4 ± 9.4% while in 
the group injected with the combination of MIC10 + p24B  the level 
was 76.3 ± 7.6%. 
The rates of vertical transmission within the litters in each group 
were also  quite variable - rates in  Group 3 range from 7%  up  to 
93%; in Group 4 they range from 0% to 81%; in Group 5 they range 
from13% to 87%; in Group 6 they range from 21% to 100%; in Group 
7 they range from 33% to 88%; in Group 8 they range from 38% to 
80%; in Group 9 they range from 27% to 100% and in Group 10 they 
range from 39% to 100%. 
 
 
4.  Discussion 
 
Infection with the parasite N. caninum is widespread within all 
cattle producing countries of the world and abortion losses due 
to neosporosis represent a major economic challenge [1]. As treat- 
ment options are  largely impractical (due to the size  of the animals 
involved and retention of residues) and as yet largely unexplored, 
the market for  a possible vaccine is therefore globally signiﬁcant 
and so  the development of  vaccines for  neosporosis represents 
a  signiﬁcant commercial opportunity within the animal health 
industry. Clearly a vaccine that prevents infection by  N. caninum 
in cattle may differ signiﬁcantly in its form from a vaccine that pre- 
vents abortion. Prior knowledge on  the development of vaccines 
against other parasites (such as the one developed against a closely 
related parasite, T. gondii) suggests the latter is more likely to be 
developed and to be efﬁcacious. 
Although vaccines for  parasites, based on  recombinant pro- 
teins, have been promised for a long time, few  have actually been 
achieved. Recombinant vaccines should be  able to be  more easily 
and more cost-effectively produced. A subunit vaccine for poultry 
coccidiosis is available [21],  however because the vaccine is based 
on  native proteins, it is difﬁcult to manufacture. Nevertheless the 
vaccine has now been used in millions of chickens around the world, 
thereby conﬁrming the need for a commercial vaccine. The greatest 
  
 
 
success stories thus far, are  the development of highly efﬁcacious 
recombinant vaccines for  Taenia  ovis  in  sheep, Taenia  saginata in 
cattle, Taenia solium in pigs and Echinococcus granulosus in livestock 
[22]. In the absence of commercial markets for these products in the 
developed world however, these vaccines have failed to prosper. 
The aim  of this study was to evaluate four recombinant proteins 
derived from N. caninum as  the basis of a potential vaccine. Two 
of the proteins are  well known (GRA1, GRA2) since they were ﬁrst 
described in detail from T. gondii.  The fourth protein p24B  is novel 
and not previously described before, despite the fact  that a homo- 
logue of this gene was detected by database searches in T. gondii and 
E. tenella. A cDNA coding for this protein was initially identiﬁed as 
an  EST possessing sequence similarity to a gene encoding a mam- 
malian immunoregulatory molecule. Database searches with the 
24B cDNA sequence identiﬁed a region within the 5t untranslated 
region that possessed sequence similarity with the 3t untranslated 
region of the MIP1a cDNA. Blum et al. (1990) argued the 3t untrans- 
lated region of this mRNA possessed important regulatory motifs 
such as  the NFxB -binding site.   However,  none of  these motifs 
appear to be in the region found in the 24B cDNA. The signiﬁcance of 
the sequence similarity of the N. caninum sequence to the data from 
MIP1a remains unknown, as does the function of this molecule in 
the tachyzoite. To date, we have been unable to determine the intra- 
cellular location of the native 24B polypeptide by ﬂuorescent or IEM 
methods. 
As an  initial approach to the development of a vaccine against 
abortion in cattle we  assessed the ability of various recombinant 
protein formulations to prevent transplacental transmission of a 
challenge infection in  a  pregnant mouse model. The  model we 
used was described by  us  previously and is  of  the immuniza- 
tion/challenge type, in that mice are injected with potential vaccine 
formulations and then challenged during pregnancy by a virulent 
strain of N. caninum that we  previously demonstrated is passed in 
utero to fetal mice [14,17]. Infection can  then be monitored by PCR 
of DNA extracted from the brains of pups that are  subsequently 
born. The  model is complex and labour intensive,  taking several 
months to complete. In addition the PCR of pup brains is also  open 
to issues of contamination and assay sensitivity that may confound 
estimates of transmission. Despite these issues, the use  of a mouse 
model remains a much more rapid and cost-effective approach for 
the preliminary assessment of  vaccines than the use  of  a  cattle 
model. 
Our previous studies using this pregnant mouse model showed 
that a live infection with NC-Nowra tachyzoites given before preg- 
nancy provided high levels of protection against fetal infection 
resulting from a challenge infection given during pregnancy [14]. 
Extension of  these studies to cattle showed that cattle immu- 
nized with live  tachyzoites were protected against a foetopathic 
challenge, whereas cattle injected with lysate were not [15].  Con- 
sequently we  have pioneered with our  studies on  transplacental 
transmission in mice, since our  data and experience suggest that 
protection against fetal infection in mice appears to be a reasonable 
predictor for protection against fetal loss  in cattle [14,15]. 
Our  results from the use  of this pregnant mouse model show 
that, in  contrast to the high level of protection induced by  a live 
infection by  NC-Nowra in  preventing fetal infection in utero, the 
levels of protection provided by  any  of the recombinant proteins 
were, at best, minimal. A combination of MIC10 and p24B in exper- 
iment 1 did reduce fetal infection by 33% (in one experiment only), 
which remains the best protection we  have achieved to date with 
a recombinant protein or lysate. 
The  signiﬁcance of the protection seen in  these studies, how- 
ever, was difﬁcult to determine because of the degree of variation 
detected within and between the treatment groups. Nevertheless, 
the presence of strong protective immunity,  when induced by  a 
live infection, was easily detectable and suggests the mouse model 
is appropriate for assessment of vaccine formulations. One  impor- 
tant observation that continues to emanate from our  studies is 
the correlation of the IgG isotype proﬁle and prevention of fetal 
infection in utero. A live  infection by NC-Nowra produces a strong 
IgG2a  response whereas a  lysate produces a  stronger IgG1  [23]. 
Interestingly the data on  the recombinant proteins suggests the 
formulations also  induced an  antibody response that was similar 
to that produced by the lysate (i.e. a stronger IgG1 response) before 
a challenge was given. After challenge, when all groups of mice had 
a strong N. caninum antibody response, the NC-Nowra lysate group 
was the only one that still  had a dominant IgG1  response. Those 
mice that were injected with either recombinant protein or a live 
infection showed a dominant IgG2a response. Previous studies with 
live  infections have shown that an  IgG1 response in the mouse is 
not protective against N. caninum infection [24]. The importance of 
gamma interferon and a Th1  style immune response is well doc- 
umented to be  important in  control of  immunity to N. caninum 
[25,26]. 
These results suggest that more consideration should be given 
to the formulation of the immunogen, including trialing of other 
adjuvants that may induce an  appropriate immune response, as 
monitored by the induction of IgG2a before challenge in this mouse 
model. VSA-3 was chosen for these studies as it is known to induce a 
strong Th1 response. The choice of antigens used in further vaccine 
trials will  also  be important. 
Several studies have investigated the vaccine potential of pro- 
teins/antigens from N. caninum. One  that is emerging as  a strong 
vaccine candidate is SRS2 which is an  antigen found on  the sur- 
face of the tachyzoite. Ironically, in the mouse it induces a Th2 style 
immune response that prevents transplacental transmission in the 
mouse of a challenge infection [27].  Expression of SRS2 from live 
expression vectors based on vaccinia virus or Brucella  abortus pro- 
vided protection against fetal infection [28]  or a lethal infection in 
mice [29]. Surprisingly SRS2 expressed in B. abortus did not provide 
protection against fetal infection in another study [30]  and it is not 
clear why. In passing we note that a live B. abortus vector is unlikely 
to be acceptable in a commercial vaccine formulation, in particular 
in countries that have achieved freedom from brucellosis in their 
livestock. 
GRA2 is another immunodominant antigen of N. caninum [12]. 
Within the ﬁeld of toxoplasmosis, it  has  received a great deal of 
attention because of its  important role as a dense granule protein 
that is involved in the biology of the parasitophorous vacuole [31]. 
In our studies we were unable to demonstrate any evidence that this 
antigen is a promising vaccine candidate, even though expression in 
B. abortus resulted in the induction of partial protection against fetal 
infection in  a pregnant mouse model [30].  Clearly the method of 
delivery of an antigen can, like many other variables in vaccination, 
also  inﬂuence the outcome of the vaccination process. 
The  present study shows that the recombinant antigens deliv- 
ered in the present formulations provided only limited amounts of 
protective immunity in the mouse model. This  may be  related to 
the type of immune response that was induced, and future work 
with recombinant proteins might be directed at trying to drive the 
host’s immune response towards an  IgG2  (Th1)  – type response. 
The  pregnant mouse model may thus continue to be  of on-going 
use  in trialing vaccine candidates for the prevention of N. caninum 
infections. 
Attenuated live vaccines are attractive as the basis of a live “vac- 
cination” approach to control bovine abortion due to neosporosis. A 
number of approaches for attenuation are  possible and some have 
been described for  N. caninum. Temperature sensitive mutants of 
N. caninum were generated that did  not persist or cause obvious 
pathology in  the brain of  infected mice [32].  Another approach 
  
 
involved irradiation of  tachyzoites, a  treatment that suppressed 
parasite multiplication leading to a parasite population that was 
attenuated in their ability to cause disease in the mouse [33].  Both 
of  these approaches, however,  lead to the generation of  mutant 
populations of parasites, whose genotypes and phenotypes are  not 
well deﬁned. Vaccination with a naturally attenuated isolate of N. 
caninum (NC-Nowra) provides  a  high level of  protection against 
transplacental transmission of N. caninum in mice [14]  and foetal 
loss in cattle [15]. The risks associated with using live parasite popu- 
lations as live vaccines in cattle may be signiﬁcant, and the potential 
for reversion to a disease causing phenotype is always a concern. It 
remains to be seen whether a live  vaccine can  become a commer- 
cial reality, however data on the prevalence of N. caninum in cattle 
suggests that a viable market exists for such a product [1,34]. 
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